Játtað í:
2020

Granskingarøki:
Heilsuvísindi

Verkætlanarslag:
Verkætlan

Verkætlanarheiti:
At eyðmerkja ílegur, sum kunnu elva til bróstkrabba í Føroyum, og kanna sambandið hjá hesum ílegum við ávísar bróstkrabba biomarkørar.

Játtanarnummar:
0351

Verkætlanarleiðari:
Noomi O. Gregersen

Stovnur/virki:
Ílegusavnið

Aðrir luttakarar:
Professor Anna-Marie Axø Gerdes,

Verkætlanarskeið:
01.08.2020 - 31.08.2021

Samlaður kostnaður:
kr. 1.272.329

Stuðul úr Granskingargrunninum:
kr. 847.572

Verkætlanarlýsing:
Breast cancer is the most common cancer type and the leading cause of cancer-related deaths among women. Breast cancer is a heterogeneous disease, where both genetics and lifestyle factors are implicated in the aetiology. Especially, deleterious mutations in the BRCA1 and BRCA2 genes are leading causes of hereditary breast cancer. Currently, the Faroese Healthcare system has no routine screening program for breast cancer susceptibility genes in the Faroe Islands. Therefore, Faroese breast cancer patients are being genetic tested at the Rigshospitalet in Copenhagen, Denmark. To our knowledge no BRCA1 or BRCA2 mutations have been identified in the Faroese breast cancer patients so far. In order to develop an optimal diagnostic strategy for breast cancer and to move toward a more personalized clinical management of the disease in the Faroe Islands it is crucial to confirm the lack or presence of BRCA1 and BRCA2 mutations, as well as any breast cancer susceptibility genes in the Faroese population. The current proposal will explore the pathogenesis of breast cancer in the Faroese population. The goal is to identify breast cancer susceptibility genes and their correlation with predictive biomarker, such as estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2). Further, by identifying founder mutations in combination with common genetic risk factors, a population specific strategy for mutation screening could be considered. Overall, the present project will bring the Faroese patients the needed access to molecular genetic diagnostics of their breast cancer, which will be of importance for their treatment and genetic counselling.

Støða:
Fer í gongd



<< Back
Administration     English